AS 202
Alternative Names: AS-202; TAK-212Latest Information Update: 27 Sep 2023
At a glance
- Originator AcuraStem
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action PIKFYVE protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Frontotemporal dementia
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 25 Sep 2023 Takeda in-licenses PIKFYVE targeted therapeutics from AcuraStem
- 15 Dec 2021 Pharmacodynamic data from a preclinical trial in Amyotrophic lateral sclerosis released by Accurastem
- 25 May 2021 AcuraStem announces intention to submit IND to the regulatory body for Amyotrophic lateral sclerosis in 2022